Molecular Residual Disease (MRD) surveillance continues to improve the lives of patients by providing actionable feedback weeks to months faster than that of legacy biomarkers such as imaging tests. This session is a roundtable discussion about the best practices in analytic validation of MRD assays with members of the scientific community representing assay developers, clinical testing laboratories, and reference standard providers focusing on best practices and concerns for analytic validation of tumor-informed assays and tumor agnostic assays.
